In another Phase I trial, DNX‐2401 has been used in recurrent GBM, showing a marked increase in CD4+ and CD8+ T‐cells, NK cells, and Th1 cytokines (IFN‐γ, TNF‐α) in the cerebrospinal fluid [31]. This evidence concerns the gene CD8A and glioblastoma.